Organotypic brain slice cultures to model neurodegenerative proteinopathies

• Published in: Molecular neurodegeneration Vol. 14; no. 1; p. 45
• Main Authors: Croft, C L, Futch, H S, Moore, B D, Golde, T E
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 02.12.2019; BioMed Central; BMC
• Subjects: Advantages; Advertising executives; Alzheimer's disease; Amyloid-β; Animals; Brain; Brain research; Brain slice preparation; Cell culture; Central nervous system; Health aspects; Medical research; Nervous system; Nervous system diseases; Neurodegeneration; Neurodegenerative diseases; Neurophysiology; Neurosciences; Novels; Organotypic brain slice cultures; Proteinopathies; Review; Spinal cord; Studies; Tau; Technology; Therapeutic applications; Therapeutics; Alzheimer’s disease; Neurodegeneration; Organotypic brain slice cultures; Tau; Recombinant adeno-associated virus; Amyloid-β; Proteinopathies; Microglia
• ISSN: 1750-1326; 1750-1326
• DOI: 10.1186/s13024-019-0346-0

Organotypic slice cultures of brain or spinal cord have been a longstanding tool in neuroscience research but their utility for understanding Alzheimer's disease (AD) and other neurodegenerative proteinopathies has only recently begun to be evaluated. Organotypic brain slice cultures (BSCs) represent a physiologically relevant three-dimensional model of the brain. BSCs support all the central nervous system (CNS) cell types and can be produced from brain areas involved in neurodegenerative disease. BSCs can be used to better understand the induction and significance of proteinopathies underlying the development and progression of AD and other neurodegenerative disorders, and in the future may serve as bridging technologies between cell culture and in vivo experiments for the development and evaluation of novel therapeutic targets and strategies. We review the initial development and general use of BSCs in neuroscience research and highlight the advantages of these cultures as an ex vivo model. Subsequently we focus on i) BSC-based modeling of AD and other neurodegenerative proteinopathies ii) use of BSCs to understand mechanisms underlying these diseases and iii) how BSCs can serve as tools to screen for suitable therapeutics prior to in vivo investigations. Finally, we will examine i) open questions regarding the use of such cultures and ii) how emerging technologies such as recombinant adeno-associated viruses (rAAV) may be combined with these models to advance translational research relevant to neurodegenerative disorders.